Glaukos ( (GKOS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shares of Glaukos Corp. have surged following an upgrade by Mizuho, which shifted its rating from Neutral to Outperform. The upgrade is driven by the potential of Glaukos’s iDose device to revolutionize the U.S. glaucoma treatment market. Mizuho’s optimism is backed by expert opinions that emphasize Glaukos’s leadership in drug-device combinations. They forecast significant earnings growth, projecting up to $7 per share by 2030, and sales exceeding $1 billion, highlighting the substantial market opportunity for Glaukos.
More about Glaukos
YTD Price Performance: 2.19%
Average Trading Volume: 552,906
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.43B
For further insights into GKOS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.